Clinical and laboratory evaluation of amorphous nano-silica in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
The aim of this study was clinical and laboratory evaluation of amorphous nano-silica in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). Materials and methods. The investigation was conducted in Kyiv Endocrine Centre in 2015–2017. 105 patients with type 2 DM and NAFLD have been followed up. We used amorphous nano-silica in suspension for treatment of NAFLD. Clinical and biochemical data were used for evaluation of treatment. Results. There was found decreasing of alanine aminotransferase, aspartate aminotransferase, total bilirubin levels, the data of waist and thigh circumference and de Ritis ratio in the treatment group and also decreasing of the glycated hemoglobinlevel in the treatment and comparison group. Conclusions. The amorphous nano-silica has hepatoprotective effect, leads to the compensation of DM and reduction of anthropometric data and can be recommended for the treatment of patients with type 2 DM and NAFLD.
